Proteon Therapeutics to Present at the Oppenheimer

WALTHAM, Mass., March 17, 2017 (GLOBE NEWSWIRE) -- Proteon Therapeutics Inc. (Nasdaq: PRTO ), a company developing novel, first-in-class therapeutics to address the medical needs of patients with kidney and vascular diseases, today announced that Company management will present at the Oppenheimer 27 ^th Annual Healthcare Conference in New York City on Wednesday, March 22, 2017 at 1:35 p.m. ET.

A live audio webcast of the presentation can be accessed by visiting the Investor and Media section of the Company’s website at www.proteontherapeutics.com .  A replay of the webcast will be archived on the Proteon website following the presentation. 

About Proteon Therapeutics

Proteon Therapeutics is committed to improving the health of patients with kidney and vascular diseases through the development of novel, first-in-class therapeutics. Proteon's lead product candidate, vonapanitase, is an investigational drug intended to improve hemodialysis vascular access outcomes. Proteon is currently enrolling patients in PATENCY-2, a Phase 3 clinical trial evaluating vonapanitase in patients with chronic kidney disease (CKD) undergoing surgical creation of a radiocephalic arteriovenous fistula for hemodialysis. Proteon is also evaluating vonapanitase in a Phase 1 clinical trial in patients with peripheral artery disease (PAD). For more information, please visit www.proteontx.com .

Investor Contact George Eldridge, Proteon Therapeutics, Senior Vice President and Chief Financial Officer 781-890-0102 geldridge@proteontherapeutics.com

Media Contact Ann Stanesa, Ten Bridge Communications 617-230-0347 proteon@tenbridgecommunications.com